Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

A Global Respiratory Perspective on the COVID-19 Pandemic: Commentary and Action Proposals

Teresa To, Giovanni Viegi, Alvaro Cruz, Luis Taborda-Barata, Monica Asher, Digambar Behera, Kazi Bennoor, Louis-Philippe Boulet, Jean Bousquet, Paulo Camargos, Claudia Conceiçao, Sandra Gonzalez Diaz, Asma El-Sony, Marina Erhola, Mina Gaga, David Halpin, Letitia Harding, Tamaz Maghlakelidze, Mohammad Reza Masjedi, Yousser Mohammad, Elizabete Nunes, Bernard Pigearias, Talant Sooronbaev, Rafael Stelmach, Ioanna Tsiligianni, Le Thi Tuyet Lan, Arunas Valiulis, Chen Wang, Sian Williams, Arzu Yorgancioglu
European Respiratory Journal 2020; DOI: 10.1183/13993003.01704-2020
Teresa To
1The Hospital for Sick Children, Dalla Lana School of Public Health, University of Toronto, Ontario, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Giovanni Viegi
2CNR Institutes of Clinical Physiology, Pisa, and Biomedical Research and Innovation, Palermo, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alvaro Cruz
3ProAR Foundation and Federal University of Bahia, Salvador, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luis Taborda-Barata
4Department of Allergy & Clinical Immunology, Cova da Beira University Hospital Centre, Covilhã, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Monica Asher
5Department of Paediatrics and Child Health, University of Auckland, Auckland, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Monica Asher
Digambar Behera
6OSD, All India Institutes of Medical Sciences (AIIMS), Raebareli, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kazi Bennoor
7Department of Respiratory Medicine, National Institute of Diseases of the Chest and Hospital, Dhaka, Bangladesh
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Louis-Philippe Boulet
8Québec heart and Lung Institute, Laval University, Québec, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean Bousquet
9MACVIA-France, Fondation Partenariale FMC VIA-LR, CHRU Arnaud de Villeneuve, Montpellier, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paulo Camargos
10Universidade Federal de Minas Gerais, Faculdade de Medicina, Departamento de Pediatria, Belo Horizonte, Minas Gerais, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Claudia Conceiçao
11Instituto de Higiene e Medicina Tropical, Institute of Tropical Medicine and Hygiene, NOVA University of Lisbon, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sandra Gonzalez Diaz
12Hospital Universitario y Facultad de Medicina, Monterrey Nuevo Leon, Mexico
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Asma El-Sony
13Public Health Epidemiological Laboratory [Epi Lab] for Research and Development, Khartoum, Sudan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marina Erhola
14Division of Health and Social Service, Finnish Institute for Health and Welfare, Helsinki, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mina Gaga
15Respiratory Medicine Department, Asthma Cen, Athens Chest Hospital, Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mina Gaga
David Halpin
16University of Exter Medical School, College of Medicine and Health, Exeter, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Letitia Harding
17Asthma and Respiratory Foundation, Wellington, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tamaz Maghlakelidze
18Ivane Javakhishvili Tbilisi State University, Pulmonology Department, Chapidze Emergency Cardiology Center, Tbilisi, Georgia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mohammad Reza Masjedi
19Shahid Beheshti University of Medical Sciences, Tehran, Iran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yousser Mohammad
20National Center for Research inn Chronic Respiratory Diseases, Tishreen University, School of Medicine, Latakia, Syria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elizabete Nunes
21Pulmonology Department, Maputo Central Hospital, Maputo, Mozambique
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bernard Pigearias
22Espace Francophone de Pneumologie, La Maison du poumon, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Talant Sooronbaev
23Kyrgyzstan National Centre of Cardiology and Internal Medicine, Euro-Asian Respiratory Society, Bishkek, Kyrgyzstan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rafael Stelmach
24ProAR Foundation and Heart Institute (InCor) Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ioanna Tsiligianni
25International Primary Care Respiratory Group; Department of Social Medicine, Faculty of Medicine, University of Crete, Heraklion, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ioanna Tsiligianni
Le Thi Tuyet Lan
26Respiratory Care Center, University Medical Center, Ho Chi Minh City, Vietnam
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arunas Valiulis
27Clinic of Children's Diseases, Institute of Clinical Medicine, and Department of Public Health, Institute of Health Sciences, Vilnius University, Vilnius, Lithuania
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chen Wang
28Peking Union Medical College, Chinese Academy of Medical Science, Beijing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sian Williams
29International Primary Care Respiratory Group, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arzu Yorgancioglu
30Department of Pulmonology, Medical Faculty, Celal Bayar University, Manisa, Turkey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

This paper offers practical and feasible actions to be implemented at patient, health care provider and community level to combat COVID-19 while attending, maintaining and strengthening ongoing health management in people with lung diseases.

INTRODUCTION

The novel coronavirus disease (COVID-19) is caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) [1, 2]. The World Health Organisation (WHO) declared the COVID-19 outbreak a pandemic on March 11, 2020, demanding effective national and global mitigation measures, strong public health response and coordination. To date, the SARS-CoV-2 pandemic has affected over 5 million individuals worldwide with an overall 7.02% (median: 3.41%, ranges: 0.06% to 31.25%) case-fatality ratio (European Center for Disease Prevention and Control dashboard: www.ecdc.europa.eu, as of May 22, 2020) [3]. This ratio may be overstated since it is based primarily on hospitalised or notified cases.

Lung diseases affect hundreds of millions of people around the world across all ages and levels of socioeconomic status. According to the Global Burden of Diseases (GBD) Study 2017, there were 3.2 million deaths due to Chronic Obstructive Pulmonary Disease (COPD) and 495 thousand deaths due to asthma [4]. Furthermore, all-age prevalent cases of chronic respiratory diseases (CRDs) totalled 545 million, of which approximately 50% due to COPD and the other 50% to asthma [5].

Despite a high burden of CRDs worldwide, CRDs (such as asthma or COPD) have not been consistently identified as a significant comorbidity for COVID-19 [6]. For example, in Wuhan, the prevalence of asthma in COVID-19 patients was merely 0.9% [7] compared to a markedly higher prevalence rates of 4.5% to 9% among the US COVID-19 patients [8, 9]. In the UK, about 14% of admitted COVID-19 patients had asthma [10], and the ISARIC (International Severe Acute Respiratory and Emerging Infection Consortium) also reported similar prevalence rates (16% with chronic pulmonary disease and 13% with asthma) [11]. In contrast, the US CDC reported CRDs (mainly asthma) as the second most prevalent comorbid condition in hospitalised COVID-19 patients aged 18–29 years [12].

These reported discrepancies may be attributable to the overall under-diagnosis of CRDs, some level of protection provided by atopy [13], or the use of inhaled corticosteroids [14]. It is unclear whether patients with asthma or COPD are at higher risk to develop COVID-19 and if the risk varies depending on other socioeconomic and demographic factors [12, 15]. For example, the risk of COVID-19 infection may be higher in individuals with chronic diseases and who are in low- and middle-income countries (LMICs) with a high prevalence of malaria, pulmonary tuberculosis, or HIV co-infection. In many LMICs, accessibility to healthcare in general is suboptimal, and have worsened not only by COVID-related lockdowns, but also by resource diverted/transferred to COVID-19 [16, 17]. Therefore, ensuring healthcare support to vulnerable populations in LMICs, such as timely access to adequate treatments for CRDs and other infectious diseases (TB, HIV and malaria) is paramount. Others have also suggested that therapies used by patients with CRDs may reduce the risk of infection or of developing symptoms leading to diagnosis [15]. Lower respiratory function, ineffective immunity and treatments that may increase their susceptibility to infection, are possible causes of their higher risk of unfavourable outcomes after a common cold, influenza or other infections [18–22]. Worsening respiratory symptoms may be a result of their underlying disease or a consequence of the superimposed infection [20]. Reports from various countries ranked CRDs among the most frequent comorbidities associated with ICU admissions, need for mechanical ventilation and deaths [15, 20, 23, 24]. A recent systematic review and meta-analysis [25] also reported a 4-fold increased odds of COPD and the development of severe COVID-19 and a 2-fold odds of ongoing smoking and the development of severe COVID-19. However, today, there is still uncertainty regarding the actual magnitude of the risks of unfavorable outcomes attributable to COVID-19 in patients with CRDs.

Further research is needed to fully understand the association between underlying CRDs and COVID-19.

ACTION PROPOSALS

The authors of this paper are active members of the Global Alliance against chronic Respiratory Diseases (GARD, www.gard-breathefreely.org/), a WHO alliance consists of national and international organisations, medical and scientific societies, patient organisations, institutions and agencies, all working with the common goal of reducing the global burden of CRDs. GARD members are frontline health care providers and researchers from over 80 countries. Our shared vision is a world where all people breathe freely and our activities are divided into four areas: advocacy, partnership, national plans on prevention and control and surveillance. In this document, we summarise our hands-on experience and lessons learned according to three perspectives: 1) patient level: interactions with health care providers; 2) health care provider level: real-time experience sharing; and 3) community level: environmental impact, air pollution.

Our main focus remains on actions concerning CRDs in the context of the pandemic. Globally, many people with underdiagnosed and undertreated CRDs, are at risk of complications from COVID-19. We should therefore ask: What can we do about it? Our reflections and experiences are still evolving with the pandemic, and we hope that they may foster deeper thoughts and considerations into how to move forward in relation to the heavy respiratory burden in times of COVID-19.

Patient Level (including Interactions with Health care Providers)

Using the National Health Insurance data between January 2000 and August 2003 to study the impacts of the previous severe acute respiratory syndrome (SARS) epidemic on medical service utilisation in Taiwan, Chang et al. reported significant reductions in ambulatory care (23·9%) and inpatient care (35·2%) during the 2002–2004 SARS epidemic [26]. This was largely attributed to the fears of SARS that generated a widespread avoidance of the health care system.

Preliminary reports suggested that this may also be occurring in the COVID-19 pandemic [27]. During the pandemic, many cities across the world were ordered to comply with social distancing, to stay at home and work from home. Individuals with a chronic condition such as asthma and COPD may opt to stay home, even when their symptoms flare up, rather than to seek health care. In general, mid- or long-term isolation or quarantine may be associated with increased levels of depression, stress and anxiety [28], and worsened symptom control and decreased quality of life in people with asthma and COPD [29–32]. Post-SARS, chronic disease patients not affected by SARS presented with worsened disease/symptom control [26].

Today, face-to-face medical consultation is not the only option. With the wide usage of smartphones, patients and health care providers are able to use readily available apps with videos (e.g. Facetime or WhatsApp) or audio via phone to conduct e-consultation and to provide routine and unscheduled “virtual visits” [33–35]. This may help patients reduce their anxiety and depression, empower disease self-management, and protect patients and health care workers during the pandemic. However, this may increase health inequity as technology use is not evenly distributed across global populations and may be particularly absent in the most at risk populations for age, cultural, education and financial reasons. COVID-19 has affected vulnerable populations disproportionately across China and the world [36]. Solid social and scientific evidence to tackle health inequity in the current COVID-19 pandemic is in urgent need.

This is a unique opportunity to promote and implement health literacy measures for the general population, with a focus on COVID-19 and CRDs. The public is anxious and eager for information. Regretfully, the information on the internet is frequently misleading, often driving one's attention away from the most important measures for prevention, early diagnosis, home isolation and identification of symptoms requiring medical care [37]. All organisations devoted to CRDs must communicate regularly with the public to deliver the key messages supported by science and endorsed by the health authorities. Communications with the use of infographics should be considered so that everyone will be able to absorb and use it. See proposed actions outlined in table 1.

View this table:
  • View inline
  • View popup
TABLE 1

Proposed Actions at the Patient Level

Health Care Provider Level (including Real-time Experience Sharing)

COVID-19 is a novel coronavirus disease. As such, the effectiveness of prevention measures, therapy options, variant phenotypes, morbidity and mortality risks, short- and long-term disease sequelae, mental health consequences and length of immunity remains unknown. Today, we are still questioning whether COVID-19 is just a respiratory disease, or affects other systems too, as suggested by cutaneous manifestations [38, 39], acute gastro-intestinal [40], neurological symptoms and cardiovascular complications in recently infected COVID-19 patients [41, 42]. Furthermore, many recovered patients continue to manifest non-respiratory symptoms and neurological morbidities which indicate the virus may have also attacked other organs such as the brain, and not just the lungs [15, 41, 43]. Further research is needed about management at home including protection of other family members, rehabilitation, diet, and the organisation of care.

Early in the epidemic, many patients were ventilated due to acute and severe respiratory failure, and many of them did not survive. The wide use of ventilation revealed a global shortage of ventilators and oxygen supply. With the shortage of medical supplies, health care providers started to implement other treatment options and some of them may not have been proven useful. The use of chatbots such as WhatsApp, Skype, Facebook Messenger and WeChat has allowed frontline health care providers to communicate with each other and share their patient experiences and consult each other in real time [44]. This collegial support has shortened the distance between people and broken communication barriers. However, information overload is a risk for busy clinicians, therefore there is a need for a strong direction from public health authorities.

During these difficult times of fighting COVID-19, health care professionals must be highly valued, including appropriate remuneration, rigorously protected and explicitly reassured any health consequences of an incidental COVID-19 will be compensated. Their confidence is built upon the support and crisis preparedness of their health care system. However, the latter varies throughout the world and warrants a higher level of collaboration in order to reduce inequalities. See proposed actions outlined in table 2.

View this table:
  • View inline
  • View popup
TABLE 2

Proposed Actions at the Health Care Provider Level

Community Level (including Environmental Impact, Air Pollution)

Air pollution has been termed the “silent killer” by the World Health Organisation as it poses a great environmental risk to health and yet often is unnoticed. Furthermore, air pollution abatement has faced multiple challenges and, with population growth and expansion of industries, many questioned whether air pollution could be ameliorated.

In February and March 2020, many cities across the world launched social distancing strategies attempting to curtail the spread of COVID-19. Cities all over the world are now observing record low levels of air pollution. For example, ambient levels of nitrogen dioxide (NO2)—one of the main traffic-related pollutants— have declined by 70% to 80% in Barcelona, 40% in London, and 50% in New York [45] and other cities across the world [46–48]. This “short-term” reduction in air pollution is a positive news out of the pandemic, however, if this short-term “improvement” will be associated with any significant health benefits, remains to be seen. Nonetheless, it demonstrated that abating air pollution is achievable. Communities that are educated and engaged more easily adhere to and are involved in epidemics prevention and treatment measures [49], although this will also depend on infrastructures, institutions, and resources [17].

It is possible that during these unusual times of less air pollution and extreme measures to avoid transmission of respiratory viruses, there is a decline in morbidity and mortality due to respiratory diseases unrelated to COVID-19, particularly those due to acute respiratory infections and/or exacerbations of CRDs. It is fundamental to reinforce surveillance and research to demonstrate how populations could benefit from more rigorous control of air pollution and transmission of respiratory viruses in general. See proposed actions outlined in table 3.

View this table:
  • View inline
  • View popup
TABLE 3

Proposed Actions at the Local and Community Level

CONCLUSION

Worldwide, COVID-19 has infected over five million people, killed hundreds of thousands and forever changed our daily life and the way we interact with each other. At the same time, globally 1000 people die from asthma every day and many of these deaths are premature and preventable with proper and timely management (www.globalasthmareport.org/burden/mortality.php). Therefore, it is paramount to minimise the potential “collateral damage” to patients from sub-optimal management of CRDs during the pandemic.

To combat the unprecedented global atrocity of COVID-19, we observed that health care professionals are united to face this deadly and fast-spreading virus, finding strength, compassion, courage and solidarity among peers who are committed to prevent, manage and rehabilitate patients with this life-threatening ailment, at all levels. Now, more than ever, there is an urgent need to bridge individual and population needs and this can only be done with engagement and interaction among public health, primary and secondary care.

The COVID-19 pandemic, while devastating, has created a remarkable worldwide opportunity for individuals, organisations and countries to excel in solidarity, collaboration and partnership, sharing resources and experiences which are essential to control the pandemic, reduce the death toll and attenuate the socio-economic and psychological consequences from isolation, unemployment and poverty.

Acknowledgement

All authors are active leaders of organisations comprising the network of the Global Alliance against chronic Respiratory Diseases (GARD), but the content and opinions expressed in this paper are those of the authors and they do not purport to reflect the opinions, views, positions or standing policies of any organisations, agencies or institutions which the authors are affiliated with.

Footnotes

  • Conflict of interest: Dr. To has nothing to disclose.

  • Conflict of interest: Dr. VIEGI has nothing to disclose.

  • Conflict of interest: Dr. Cruz has nothing to disclose.

  • Conflict of interest: Dr. Taborda-Barata reports that he has received honoraria from AstraZeneca, Novartis, Menarini, and Vitoria Laboratories as payment for giving scientific lectures in the context of trainining sessions in the respiratory field or allergy, for healthcare professionals.

  • Conflict of interest: Dr. Asher has nothing to disclose.

  • Conflict of interest: Dr. BEHERA has nothing to disclose.

  • Conflict of interest: Dr. Bennoor has nothing to disclose.

  • Conflict of interest: Dr. Boulet has nothing to disclose.

  • Conflict of interest: Dr. Bousquet reports personal fees from Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Purina, Sanofi-Aventis, Takeda, Teva, Uriach, other from KYomed-Innov, outside the submitted work.

  • Conflict of interest: Dr. Camargos has nothing to disclose.

  • Conflict of interest: Dr. Conceição has nothing to disclose.

  • Conflict of interest: Dr. Gonzalez Diaz has nothing to disclose.

  • Conflict of interest: Dr. El-Sony has nothing to disclose.

  • Conflict of interest: Dr. Erhola has nothing to disclose.

  • Conflict of interest: Dr. Gaga reports grants and personal fees from Novartis, grants from Galapagos, personal fees from BMS, personal fees from MSD, personal fees from AZ, grants and personal fees from Menarini, grants from Elpen, from null, outside the submitted work;.

  • Conflict of interest: Dr. Halpin reports personal fees from AstraZeneca, personal fees and non-financial support from Boehringer Ingelheim, personal fees from Chiesi, personal fees from GlaxoSmithKline, personal fees from Novartis, personal fees from Pfizer, personal fees and non-financial support from Novartis, personal fees from Sanofi, outside the submitted work;.

  • Conflict of interest: Dr. Harding has nothing to disclose.

  • Conflict of interest: Dr. Maglakelidze has nothing to disclose.

  • Conflict of interest: Dr. Masjedi has nothing to disclose.

  • Conflict of interest: Dr. Mohammad has nothing to disclose.

  • Conflict of interest: Dr. NUNES has nothing to disclose.

  • Conflict of interest: Dr. Pigearias has nothing to disclose.

  • Conflict of interest: Dr. Sooronbaev has nothing to disclose.

  • Conflict of interest: Dr. Stelmach reports grants from São Paulo Research Foundation, grants and personal fees from Novartis , grants, personal fees and non-financial support from AstraZeneca, grants from MSD, grants, personal fees and non-financial support from Chiesi, personal fees and non-financial support from Boheringer Ingelheim , outside the submitted work;.

  • Conflict of interest: Dr. Tsiligianni reports grants from ELPEN, GSK HELLAS, personal fees from Novartis, Boehringer Ingelheim, GSK, Menarini, outside the submitted work;.

  • Conflict of interest: Dr. Tuyet has nothing to disclose.

  • Conflict of interest: Dr. Valiulis has nothing to disclose.

  • Conflict of interest: Dr. Wang has nothing to disclose.

  • Conflict of interest: Dr. Williams has nothing to disclose.

  • Conflict of interest: Dr. Yorgancioglu has nothing to disclose.

  • Received May 10, 2020.
  • Accepted June 5, 2020.
  • Copyright ©ERS 2020
http://creativecommons.org/licenses/by-nc/4.0/

This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.

References

  1. ↵
    1. Zhu N,
    2. Zhang D,
    3. Wang W, et al.
    A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med 2020; 382: 727–733. doi:10.1056/NEJMoa2001017
    OpenUrlCrossRefPubMed
  2. ↵
    1. WHO
    . Coronavirus disease (COVID-19) Pandemic. 2020 [cited 2020 April 19]; www.who.int/emergencies/diseases/novel-coronavirus-2919
  3. ↵
    COVID-19 Global Overview. 2020 [cited 2020 April 19]; www.qap.ecdc.europa.eu/public/extensions/COVID-19/COVID-19.html
  4. ↵
    Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018; 392: 1736–1788. doi:10.1016/S0140-6736(18)32203-7
    OpenUrlCrossRefPubMed
  5. ↵
    Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018; 392: 1789–1858. doi:10.1016/S0140-6736(18)32279-7
    OpenUrlCrossRefPubMed
  6. ↵
    1. Williamson E,
    2. Walker AJ,
    3. Bhaskaran KJ, et al.
    Factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients. MedRxiv 2020. www.doi.org/10.1101/2020.1105.1106.20092999.
  7. ↵
    1. Li X,
    2. Xu S,
    3. Yu M, et al.
    Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol 2020.
  8. ↵
    1. Richardson S,
    2. Hirsch JS,
    3. Narasimhan M, et al.
    Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA 2020: 323: 2052–2059. doi:10.1001/jama.2020.6775
    OpenUrlPubMed
  9. ↵
    1. Parodi SM,
    2. Liu VX
    . From Containment to Mitigation of COVID-19 in the US. JAMA 2020.
  10. ↵
    1. Docherty AB,
    2. Harrison EM,
    3. Green CA, et al.
    Features of 16,749 hospitalised UK patients with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol. MedRxiv 2020. 2020.2004.2023.20076042.
  11. ↵
    1. ISARIC
    . International Severe Acute Respiratory and emerging Infection Consortium 6th May 2020 Report. Oxford, UK; 2020.
  12. ↵
    1. Garg S,
    2. Kim L,
    3. Whitaker M, et al.
    Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 - COVID-NET, 14 States, March 1–30, 2020. MMWR Morb Mortal Wkly Rep 2020; 69: 458–464. doi:10.15585/mmwr.mm6915e3
    OpenUrlCrossRefPubMed
  13. ↵
    1. Jackson DJ,
    2. Busse WW,
    3. Bacharier LB, et al.
    Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2. J Allergy Clin Immunol 2020.
  14. ↵
    1. Peters MC,
    2. Sajuthi S,
    3. Deford P, et al.
    COVID-19 Related Genes in Sputum Cells in Asthma: Relationship to Demographic Features and Corticosteroids. Am J Respir Crit Care Med 2020.
  15. ↵
    1. Halpin DMG,
    2. Faner R,
    3. Sibila O, et al.
    Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection? Lancet Respir Med 2020; 8: 436–438. doi:10.1016/S2213-2600(20)30167-3
    OpenUrl
  16. ↵
    1. Amimo F,
    2. Lambert B,
    3. Magit A
    . What does the COVID-19 pandemic mean for HIV, tuberculosis, and malaria control? Trop Med Health 2020; 48: 32. doi:10.1186/s41182-020-00219-6
    OpenUrl
  17. ↵
    1. Adepoju P
    . Tuberculosis and HIV responses threatened by COVID-19. Lancet HIV 2020; 7: e319–e320. doi:10.1016/S2352-3018(20)30109-0
    OpenUrl
  18. ↵
    1. Belongia EA,
    2. King JP,
    3. Kieke BA, et al.
    Clinical Features, Severity, and Incidence of RSV Illness During 12 Consecutive Seasons in a Community Cohort of Adults >/=60 Years Old. Open Forum Infect Dis 2018; 5: ofy316. doi:10.1093/ofid/ofy316
    OpenUrl
    1. Greenberg SB,
    2. Allen M,
    3. Wilson J, et al.
    Respiratory viral infections in adults with and without chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 162: 167–173. doi:10.1164/ajrccm.162.1.9911019
    OpenUrlCrossRefPubMedWeb of Science
  19. ↵
    1. Linden D,
    2. Guo-Parke H,
    3. Coyle PV, et al.
    Respiratory viral infection: a potential “missing link” in the pathogenesis of COPD. Eur Respir Rev 2019; 28: 180063. doi:10.1183/16000617.0063-2018
    OpenUrlAbstract/FREE Full Text
    1. Mallia P,
    2. Message SD,
    3. Gielen V, et al.
    Experimental rhinovirus infection as a human model of chronic obstructive pulmonary disease exacerbation. Am J Respir Crit Care Med 2011; 183: 734–742. doi:10.1164/rccm.201006-0833OC
    OpenUrlCrossRefPubMedWeb of Science
  20. ↵
    1. Wark PA,
    2. Tooze M,
    3. Powell H, et al.
    Viral and bacterial infection in acute asthma and chronic obstructive pulmonary disease increases the risk of readmission. Respirology 2013; 18: 996–1002. doi:10.1111/resp.12099
    OpenUrlCrossRefPubMedWeb of Science
  21. ↵
    1. Khaltaev N
    . GARD, a new way to battle with chronic respiratory diseases, from disease oriented programmes to global partnership. J Thorac Dis 2017; 9: 4676–4689. doi:10.21037/jtd.2017.11.91
    OpenUrl
  22. ↵
    1. Guan WJ,
    2. Liang WH,
    3. Zhao Y, et al.
    Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis. Eur Respir J 2020; 55: 2000547. doi:10.1183/13993003.00547-2020
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Zhao Q,
    2. Meng M,
    3. Kumar R, et al.
    The impact of COPD and smoking history on the severity of Covid-19: A systemic review and meta-analysis. J Med Virol 2020.
  24. ↵
    1. Chang HJ,
    2. Huang N,
    3. Lee CH, et al.
    The impact of the SARS epidemic on the utilization of medical services: SARS and the fear of SARS. Am J Public Health 2004; 94: 562–564. doi:10.2105/AJPH.94.4.562
    OpenUrlCrossRefPubMedWeb of Science
  25. ↵
    1. Lazzerini M,
    2. Barbi E,
    3. Apicella A, et al.
    Delayed access or provision of care in Italy resulting from fear of COVID-19. Lancet Child Adolesc Health 2020; 4: e10–e11. doi:10.1016/S2352-4642(20)30108-5
    OpenUrlCrossRefPubMed
  26. ↵
    1. Brooks SK,
    2. Webster RK,
    3. Smith LE, et al.
    The psychological impact of quarantine and how to reduce it: rapid review of the evidence. Lancet 2020; 395: 912–920. doi:10.1016/S0140-6736(20)30460-8
    OpenUrlCrossRefPubMed
  27. ↵
    1. Bratek A,
    2. Zawada K,
    3. Beil-Gawelczyk J, et al.
    Depressiveness, symptoms of anxiety and cognitive dysfunctions in patients with asthma and chronic obstructive pulmonary disease (COPD): possible associations with inflammation markers: a pilot study. J Neural Transm (Vienna) 2015; 122 Suppl 1: S83–S91. doi:10.1007/s00702-014-1171-9
    OpenUrl
    1. Di Marco F,
    2. Verga M,
    3. Santus P, et al.
    Close correlation between anxiety, depression, and asthma control. Respir Med 2010; 104: 22–28. doi:10.1016/j.rmed.2009.08.005
    OpenUrlCrossRefPubMed
    1. Gonzalez-Freire B,
    2. Vazquez I,
    3. Pertega-Diaz S
    . The Relationship of Psychological Factors and Asthma Control to Health-Related Quality of Life. J Allergy Clin Immunol Pract 2020; 8: 197–207. doi:10.1016/j.jaip.2019.07.009
    OpenUrl
  28. ↵
    1. Gao J,
    2. Zheng P,
    3. Jia Y, et al.
    Mental health problems and social media exposure during COVID-19 outbreak. PLoS One 2020; 15: e0231924.
    OpenUrl
  29. ↵
    1. Khairat S,
    2. Meng C,
    3. Xu Y, et al.
    Interpreting COVID-19 and Virtual Care Trends: Cohort Study. JMIR Public Health Surveill 2020; 6: e18811. doi:10.2196/18811
    OpenUrl
    1. Moazzami B,
    2. Razavi-Khorasani N,
    3. Dooghaie Moghadam A, et al.
    COVID-19 and telemedicine: Immediate action required for maintaining healthcare providers well-being. J Clin Virol 2020; 126: 104345. doi:10.1016/j.jcv.2020.104345
    OpenUrl
  30. ↵
    1. Webster P
    . Virtual health care in the era of COVID-19. Lancet 2020; 395: 1180–1181. doi:10.1016/S0140-6736(20)30818-7
    OpenUrlCrossRefPubMed
  31. ↵
    1. Wang Z,
    2. Tang K
    . Combating COVID-19: health equity matters. Nat Med 2020; 26: 458. doi:10.1038/s41591-020-0823-6
    OpenUrl
  32. ↵
    1. Cuan-Baltazar JY,
    2. Muñoz-Perez MJ,
    3. Robledo-Vega C, et al.
    Misinformation of COVID-19 on the Internet: Infodemiology Study. JMIR Public Health Surveill 2020; 6: e18444. doi:10.2196/18444
    OpenUrl
  33. ↵
    1. Estebanez A,
    2. Perez-Santiago L,
    3. Silva E, et al.
    Cutaneous manifestations in COVID-19: a new contribution. J Eur Acad Dermatol Venereol 2020.
  34. ↵
    1. Recalcati S
    . Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol 2020; 34: e212–e213. doi:10.1111/jdv.16387
    OpenUrl
  35. ↵
    1. Cheung KS,
    2. Hung IF,
    3. Chan PP, et al.
    Gastrointestinal Manifestations of SARS-CoV-2 Infection and Virus Load in Fecal Samples from the Hong Kong Cohort and Systematic Review and Meta-analysis. Gastroenterology 2020.
  36. ↵
    1. Mao L,
    2. Jin H,
    3. Wang M, et al.
    Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol 2020: e201127.
  37. ↵
    1. Long B,
    2. Brady WJ,
    3. Koyfman A, et al.
    Cardiovascular complications in COVID-19. Am J Emerg Med 2020.
  38. ↵
    1. Lu L,
    2. Xiong W,
    3. Liu D, et al.
    New-onset acute symptomatic seizure and risk factors in Corona Virus Disease 2019: A Retrospective Multicenter Study. Epilepsia 2020.
  39. ↵
    1. Renwick M
    . Doctors on the front lines of COVID-19 fight living apart. The Globe and Mail 2020.
  40. ↵
    1. Querol X
    . Are the Reductions in Air Pollution Triggered by the COVID-19 Epidemic Having Health Effects? 2020 [cited 2020 April 19]; www.isglobal.org/en/healthisglobal/-/custom-blog-portlet/-sera-relevante-para-nuestra-salud-la-disminucion-de-la-contaminacion-atmosferica-durante-la-epidemia-de-la-covid-19-/5083982/11101
  41. ↵
    1. Tobías A,
    2. Carnerero C,
    3. Reche C, et al.
    Changes in air quality during the lockdown in Barcelona (Spain) one month into the SARS-CoV-2 epidemic. Sci Total Environ 2020; 726: 138540. doi:10.1016/j.scitotenv.2020.138540
    OpenUrlPubMed
    1. Mahato S,
    2. Pal S,
    3. Ghosh KG
    . Effect of lockdown amid COVID-19 pandemic on air quality of the megacity Delhi, India. Sci Total Environ 2020; 730: 139086. doi:10.1016/j.scitotenv.2020.139086
    OpenUrl
  42. ↵
    1. Dantas G,
    2. Siciliano B,
    3. França BB, et al.
    The impact of COVID-19 partial lockdown on the air quality of the city of Rio de Janeiro, Brazil. Sci Total Environ 2020; 729: 139085. doi:10.1016/j.scitotenv.2020.139085
    OpenUrl
  43. ↵
    1. Stein-Zamir C,
    2. Abramson N,
    3. Edelstein N, et al.
    Community-Oriented Epidemic Preparedness and Response to the Jerusalem 2018–2019 Measles Epidemic. Am J Public Health 2019; 109: 1714–1716. doi:10.2105/AJPH.2019.305343
    OpenUrl
    1. Vardavas CI,
    2. Nikitara K
    . COVID-19 and smoking: A systematic review of the evidence. Tob Induc Dis 2020; 18: 20. doi:10.18332/tid/119324
    OpenUrlPubMed
PreviousNext
Back to top
View this article with LENS
Vol 60 Issue 2 Table of Contents
European Respiratory Journal: 60 (2)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
A Global Respiratory Perspective on the COVID-19 Pandemic: Commentary and Action Proposals
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
A Global Respiratory Perspective on the COVID-19 Pandemic: Commentary and Action Proposals
Teresa To, Giovanni Viegi, Alvaro Cruz, Luis Taborda-Barata, Monica Asher, Digambar Behera, Kazi Bennoor, Louis-Philippe Boulet, Jean Bousquet, Paulo Camargos, Claudia Conceiçao, Sandra Gonzalez Diaz, Asma El-Sony, Marina Erhola, Mina Gaga, David Halpin, Letitia Harding, Tamaz Maghlakelidze, Mohammad Reza Masjedi, Yousser Mohammad, Elizabete Nunes, Bernard Pigearias, Talant Sooronbaev, Rafael Stelmach, Ioanna Tsiligianni, Le Thi Tuyet Lan, Arunas Valiulis, Chen Wang, Sian Williams, Arzu Yorgancioglu
European Respiratory Journal Jan 2020, 2001704; DOI: 10.1183/13993003.01704-2020

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
A Global Respiratory Perspective on the COVID-19 Pandemic: Commentary and Action Proposals
Teresa To, Giovanni Viegi, Alvaro Cruz, Luis Taborda-Barata, Monica Asher, Digambar Behera, Kazi Bennoor, Louis-Philippe Boulet, Jean Bousquet, Paulo Camargos, Claudia Conceiçao, Sandra Gonzalez Diaz, Asma El-Sony, Marina Erhola, Mina Gaga, David Halpin, Letitia Harding, Tamaz Maghlakelidze, Mohammad Reza Masjedi, Yousser Mohammad, Elizabete Nunes, Bernard Pigearias, Talant Sooronbaev, Rafael Stelmach, Ioanna Tsiligianni, Le Thi Tuyet Lan, Arunas Valiulis, Chen Wang, Sian Williams, Arzu Yorgancioglu
European Respiratory Journal Jan 2020, 2001704; DOI: 10.1183/13993003.01704-2020
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • INTRODUCTION
    • ACTION PROPOSALS
    • CONCLUSION
    • Acknowledgement
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • SARS-CoV-2-induced senescence as a potential therapeutic target
  • Are intravenous corticosteroid pulses superior to low dose corticosteroids in patients with severe Covid-19?
  • Update March 2022: management of hospitalised adults with coronavirus disease-19 (COVID-19): a European Respiratory Society living guideline
Show more Editorial

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2022 by the European Respiratory Society